Issues with Current Flu Vaccines

The current landscape of influenza vaccines face several challenges that limit their overall effectiveness and adaptability:

• Current vaccines provide only 6-8 months of protection.
• Average efficacy of seasonal influenza vaccines is only 40-60%.
• Vaccines tend to be less effective in older populations, who are at higher risk for severe complications from influenza.
• Public perception of moderate vaccine efficacy contributes to hesitancy.
• The production of egg-based vaccines can take up to 6 months, which delays response to emerging pandemic strains and limits flexibility.

ImmunoNanoMed’s Value Proposition

ImmunoNanoMed’s PBV technology revolutionizes flu vaccines by introducing room-temperature-stable, dry powder vaccines that provide broad, durable immunity against influenza. This innovative approach encapsulates multiple recombinant subunit influenza antigens and a small molecule adjuvant into polyanhydride particles, administered nasally rather than through traditional in-the-arm methods. Backed by peer-reviewed publications and patents, this technology addresses the limitations of existing flu vaccines, paving the way for the next generation of more effective, stable flu vaccines.

Our Key Differentiators

The key differentiators of our PBV technology are:

1. Needle-free delivery: Enhances adoption by addressing needle hesitancy and enabling self-administration.
2. Local lung immunity: Targets lung niches to boost immune protection against influenza.
3. Improved immunity: Provides cross-strain protection for broader defense against flu variants.
4. Faster manufacturing: Shorter production times using recombinant antigens versus traditional methods.
5. Reduced cost: Lowers costs by simplifying manufacturing and eliminating the cold chain.
6. Room temperature stability: Extends shelf life and expands global accessibility by removing the need for refrigeration.